UBS Maintains Neutral on Xylem, Lowers Price Target to $99
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
UBS analyst Joshua Spector maintains Xylem (NYSE:XYL) with a Neutral and lowers the price target from $112 to $99.
UBS analyst Joshua Spector maintains Xylem (NYSE:XYL) with a Neutral and lowers the price target from $112 to $99.
